Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of TRTL-913 in healthy adults and adults with tinnitus. The study has two parts Part A is a double-blind phase assessing 7 days of dosing in healthy volunteers to understand how the drug behaves in the body and its safety profile. Part B is an open-label phase evaluating a 2-week treatment course in adults with tinnitus to assess safety and potential benefits. Participants in Part A will be randomly assigned to receive either TRTL-913 capsules or a matching placebo once daily for 7 days. In Part B, participants with tinnitus will self-administer TRTL-913 capsules once daily for 14 days, with dosing possibly adjusted based on Part A results. The study uses a parallel design and includes careful monitoring throughout both parts. During the study, participants will undergo safety assessments including vital signs, laboratory tests, ECGs, and monitoring for adverse events. For Part B, researchers will measure changes in tinnitus severity using standard tools like the Tinnitus Functional Index and Tinnitus Handicap Inventory over 21 days. The study will also assess plasma concentrations of TRTL-913 in Part A. Participants are closely monitored for any signs of suicidal thoughts or behavior. The total study duration varies depending on the part but involves up to 21 days of observation.
Actively Recruiting
Researchers are studying the safety and effectiveness of GIA632 in people with moderate to severe cutaneous lichen planus cLP. The goal is to find the best dose of GIA632 to use in future larger studies. This is a Phase IIb trial that includes multiple dosing regimens and compares GIA632 with placebo. Participants will be randomly assigned to receive either GIA632 at one of several dose levels or a matching placebo during a 16-week double-blind treatment period. After this core period, participants can continue in a 52-week extension phase to further assess safety and effects. Finally, there is a 12-week safety follow-up period after treatment ends. During the study, participants will be assessed regularly using the Investigator Global Assessment IGA scale, peak itch rating scales, and Lichen Planus Activity and Damage Index LiPADI scores. Safety will be monitored through adverse event reports for up to 80 weeks. The total study duration includes screening, treatment, extension, and follow-up phases lasting over a year.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.
Actively Recruiting
The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness of zabalafin hydrogel in people aged 2 years and older who have mild to moderate atopic dermatitis, also known as eczema. This Phase 2b randomized, double-blind study includes two groups one with mild to moderate atopic dermatitis and another with the same condition plus a secondary skin infection. The study aims to compare zabalafin hydrogel to a placebo vehicle to understand its impact on eczema symptoms using a validated global assessment scale. Participants will be randomly assigned in a 21 ratio to receive either zabalafin 9.5% hydrogel or a placebo gel. The study treatment lasts 16 weeks following up to 2 weeks of screening. During treatment, participants will visit the clinic every 2 weeks for the first month and then monthly until the end of the study. The study evaluates not only the effectiveness but also the safety and tolerability of zabalafin compared to the placebo. Throughout the study, participants will undergo assessments including the validated Investigators Global Assessment, Eczema Area and Severity Index, pruritus itching rating, and patient-reported eczema measures. Safety monitoring and evaluation of antibacterial effects in those with skin infections are included. Participants must comply with study procedures, avoid using other topical products on the eczema lesions, and attend scheduled visits over the approximately 16-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of HB-1 compared to a placebo in adults aged 18 to 65 years diagnosed with Post-Traumatic Stress Disorder PTSD. This phase 2, multi-center, randomized, double-blind, placebo-controlled trial will include approximately 200 to 500 participants without severe neuropsychiatric or medical conditions. The study aims to better understand how HB-1 affects PTSD symptoms using established clinical assessments. Participants will receive HB-1, a dual active pharmaceutical ingredient tablet containing telmisartan and verapamil extended release, or a matching placebo. They will start with a lower dose of HB-1 taken once daily and may have their dose increased at Week 4 or Week 8 if symptoms have not sufficiently improved and no serious side effects have occurred. Treatment will continue for 12 weeks, followed by a safety follow-up one week after the last dose. Throughout the study, participants will attend visits at baseline, Week 4, Week 8, and Week 12 for symptom assessments using several clinical scales and questionnaires. Safety monitoring will include checking for adverse events, vital signs, ECGs, and lab tests. The primary outcome is the change in clinician-rated PTSD symptoms. The total participation time is about 13 weeks including treatment and follow-up.
1-10 of 12
1